Shattuck is a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease.

Biotechnology

Education

Shattuck Labs

Suresh joined Shattuck as Executive Director of Research and Development in 2017 and is one of the scientific co-inventors of the ARC technology platform. Prior to joining Shattuck, Suresh served as the Director of Research and Development at Heat Biologics, Inc. in Durham, NC, where he led external research collaborations and co-developed the ComPact cell-based vaccine platform. Suresh’s research experience spans the fields of gene therapy, infectious disease (HIV) and cancer immunotherapy where he has co-authored numerous publications in lead journals such as Cancer Immunology Research, Nature Medicine, Human Gene Therapy, and the Journal of Biological Chemistry. Suresh has also co-authored several successful federal grant applications, including two R01’s awarded from the National Institute of Allergy and Infectious Diseases (NIAID) and an R21 that was received from the [National Cancer Institute](/org/national-cancer-institute) (NCI). Suresh received his M.S. and Ph.D. from the [University of Rochester](/org/university-of-rochester), NY, and subsequently completed a successful post-doctoral fellowship at [The Ohio State University](/org/the-ohio-state-university), where he was a recipient of a Staff Career Development Grant from their College of Veterinary Medicine.

Suresh De Silva

George joined [Shattuck Labs](/org/shattuck-labs) in 2017 as the Vice President of R&D, and is one of the scientific co-inventors of the ARC platform. Previously, George served as the Senior Director of Research and Development at Heat Biologics, Inc., where he directed the Discovery and Clinical based research efforts for their phase I/II trials, and co-invented a ‘next-generation’ vaccine platform that combines a cell based immunotherapy vaccine and a T cell costimulatory fusion protein in a single treatment. He has authored IND submissions, several NIH and Private Foundation Grants, and was a recipient of an NIH T32 Training Grant Fellowship. George has also authored numerous publications in leading journals, including Cell, Molecular Cell, Genes and Development, and Blood. He received his M.S. and Ph.D. from the [University of Rochester](/org/university-of-rochester), NY and conducted his post-doctoral fellowship training with the NIH branch; National Institute of Environmental Health Sciences.

George Fromm

Amy joined Shattuck in October 2022 as Vice President of Clinical Operations. She brings over 25 years of drug development experience, including over 20 years in oncology clinical development. Prior to joining Shattuck, Amy was the Vice President of Clinical Operations at Aravive and NervGen Pharma. Her prior experience also includes multiple CROs and biotech companies, including OSI Pharmaceuticals, where Amy was the Clinical Operations lead for an IGF-1R inhibitor program. She has contributed to the conduct of dozens of clinical trials, ranging from Phase I to Phase III. Amy completed her BS in Cellular and Molecular Biology at the University of Michigan and later achieved a master’s degree in Bioethics from the University of Pennsylvania.

Amy Franke

Conor has served as the Vice President of Investor Relations since January 2023. He previously served as the Senior Director of Finance and Investor Relations from January 2021 to December 2022 and as the Director of Finance from March 2019 to January 2021. Conor joined Shattuck Labs in 2019 and brings over a decade of progressive biotechnology company management and financial experience. Conor is a certified public accountant (CPA) in the state of New York and holds an Investor Relations Charter (IRC)®. Conor received a Master of Accounting and Professional Consultancy from Villanova University and a Bachelor of Business Administration from the University of Georgia.

Conor Richardson

Dr. Metenou joined Shattuck in September 2022 as Vice President of Translational Medicine. He brings to Shattuck more than 20 years of human immunology research experience in academia and government, as well as biotech and large pharmaceutical companies. Prior to joining Shattuck, Dr. Metenou held senior leadership roles at Precigen, where he oversaw the development of therapeutic vaccines for HPV-positive tumors and associated nonmalignant tumors, in addition to designing correlative studies and biomarker plans for CAR-T therapies in solid tumor and hematological malignancies. Previously, Dr. Metenou was with Compass Therapeutics and EMD Serono (Merck KGAa), during which time he developed and implemented the biomarker strategy for avelumab. After earning his Ph.D. in Immunology at Georgetown University, Dr. Metenou completed his post-doctoral fellowship training and was a research fellow at the National Institutes of Infectious Diseases.

Simon Metenou

Thomas joined Shattuck in April 2018 as Head of Regulatory Affairs. He has more than 22 years of experience at GlaxoSmithKline, most recently as a Senior Director in Global Regulatory Affairs responsible for regulatory strategy and leading regulatory teams for global and US focused programs. Prior to regulatory affairs, Thomas was a Senior Director within oncology clinical development at GSK, leading global clinical development teams for multiple solid tumor and hematologic malignancy programs. In both regulatory and clinical roles, he has experience spanning drug development from prior to candidate selection through approval to market. Thomas was previously a co-founder and Director of the Clinical Research Center at Sarasota Memorial Hospital in Florida, an Assistant Director in the Department of Pharmaceutical Services, and Coordinator of the Institutional Review Board. Thomas has a Doctor of Pharmacy degree from [University of Illinois at Chicago](/org/university-of-illinois-at-chicago), and completed a Fellowship in Clinical Research and Drug Development at The University of North Carolina at Chapel Hill.

Thomas Lampkin

Fatima joined Shattuck in August 2018 as the VP of Clinical Development. Prior to joining Shattuck, Fatima joined GlaxoSmithKline in 2014 and then moved to [Novartis](/org/novartis) in 2015 where she was a Senior Clinical Development Medical Director and GI indications lead. Fatima completed her BA with honors in biology at University of Chicago in 1997 and then went on to the University of Cincinnati College of Medicine where she received her MD, PhD in 2005. Fatima then moved to [Duke University](/org/duke-university) where she completed internal medicine and oncology fellowship training in 2011. She then came on faculty at Duke as an assistant professor in the Division of Oncology. While at Duke, she practiced gastrointestinal oncology and was the principal investigator on multiple phase I, II and III oncology clinical trials.

Fatima Rangwala

Andrew has served as the Chief Financial Officer since March 2021. He previously served as the Vice President of Finance and Corporate Strategy from July 2020 to March 2021 and as the Vice President of Corporate Development and Strategy from May 2017 to July 2020. Andrew joined [Shattuck Labs](/org/shattuck-labs) in 2017 and provides over 10 years of biotechnology company management experience. Previously, Andrew was the co-founder of [Lumos Pharma](/org/lumos-pharma), a biopharmaceutical company focused on developing therapeutics for genetic rare diseases. Andrew holds a Master’s in Business Administration, with majors in Health Care Management and Finance, from The Wharton School at the [University of Pennsylvania](/org/university-of-pennsylvania), where he was a Kaiser Fellow. Andrew holds a Bachelors of Business Administration from [Texas Christian University](/org/texas-christian-university).

Andrew R. Neill

Dr. Shukla joined Shattuck in June of 2021 as Chief Technical Officer. He brings a background of demonstrated leadership across the full spectrum of biologics process development and manufacturing to Shattuck. Most recently Dr. Shukla served as the Chief Technical Operations Officer at Redpin Therapeutics, where he was responsible for all aspects of process, analytical and formulation development, and cGMP manufacturing. Previously, he held several senior leadership positions, including Vice President of Manufacturing at CRISPR Therapeutics, Vice President and Head of Biologics Process Development at Shire, Senior Vice President of Process Development and Manufacturing at KBI Biopharma, and in senior scientific roles at Bristol-Myers Squibb and Amgen prior to KBI. Throughout his career, Dr. Shukla has been involved in over 75 investigational new drug applications as well as the commercialization of several therapeutics, including Yervoy®, Orencia®, and Nulojix®. Dr. Shukla received his doctorate in Chemical and Biochemical Engineering from Rensselaer Polytechnic Institute and his undergraduate degree from the Indian Institute of Technology, Delhi.

Abhinav A. Shukla

Kelli joined Shattuck in January 2021 as Vice President of Quality. Prior to joining Shattuck, Kelli was the Executive Director of Quality Assurance at [Liquidia Technologies](/org/liquidia-technologies), leading the quality department for GMP, GCP, and GLP operations. Kelli has over 17 years of experience in quality assurance, covering all aspects of the pharmaceutical product lifecycle.  She received her Bachelor’s degree in Biological Engineering and a Master of Bioinformatics from [North Carolina State University](/org/north-carolina-state-university). She also holds a graduate certificate in Pharmaceutical & Medical Device Law & Compliance from Seton Hall Law School. She is a Certified Quality Manager/Operational Excellence (CMQOE) and a Certified Pharmaceutical GMP Professional (CPGMPP).

Kelli Collin

Bo joined Shattuck in April 2019 as Senior Director of Biometrics. She has over 14 years of oncology clinical development experience spanning from early to late phase in both pharmaceutical and biotechnology companies. Bo has comprehensive experience in oncology early phase clinical development and has been the statistical lead for several oncology compounds. Prior to joining Shattuck, Bo was the Senior Director of Biostatistics in early phase oncology clinical program at Medimmune/AstraZeneca.  Bo started her career as a Clinical Trial Statistician at GlaxoSmithKline (GSK) and spent eight years in oncology clinical development at GSK.  After leaving GSK, Bo spent about three years in a biotech company as the Director of Statistics.  Bo received her PhD in Biostatistics from the [University of South Carolina](/org/university-of-south-carolina).

Bo Ma

Casi joined Shattuck in December of 2019. She brings a background in management consulting and over twenty years in the healthcare and life science industries. She has held leadership roles in five US start-up businesses (private and public). Most recently Casi served as Chief Operating Officer for [ImmuneSensor Therapeutics](/org/immunesensor-therapeutics) where she was responsible for corporate strategy, start-up operations, intellectual property, oversight of the company’s first IND filing and the initiation of a first-in-human Phase 1 clinical trial. Previously, she held leadership positions including Chief Business Officer at Mirna Therapeutics, Vice President of Business Development at [Reata Pharmaceuticals](/org/reata-pharmaceuticals), Vice President of Business Development at ODC Therapy and Operations Director for Oncology at EMD Pharmaceuticals and Merck KGaA. Casi earned a B.S. in Chemistry, from [Southwestern University](/org/southwestern-university) and an M.B.A. from the McCombs School of Business at the University of Texas at Austin.

Casi Deyoung

Taylor is a co-founder of [Shattuck Labs](/org/shattuck-labs) and currently serves as Chief Executive Officer and a member of the Board of Directors. Before his appointment as CEO in January 2020, Taylor served as the company’s Chief Scientific Officer. Taylor is the lead inventor of Shattuck’s ARC technology platform. Prior to Shattuck, he served as Chief Scientific Officer of Heat Biologics, Inc. where he was a co-inventor of significant elements of Heat’s ImPACT and ComPACT technology platforms. Taylor was also the co-inventor of [Pelican Therapeutics](/org/pelican-therapeutics) ‘s TNFRSF25 agonist technology where he served as Chairman of the Scientific Advisory Board. Taylor has numerous publications in the field of tumor immunology and immunotherapy, spanning the subjects of cancer vaccines, therapeutic proteins and antibodies, adenosinergic and IDO mediated immunosuppression and regulatory T cell biology. In 2008, he received the best overall research award at the National Student Research Forum, and in 2011 he was nominated as a Future Leader in Cancer Research by the American Association for Cancer Research. Taylor received both his M.D. and Ph.D. degrees from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine. He received his B.A. in Biology from [Bucknell University](/org/lombahdo).

Taylor H. Schreiber

Jim has over 25 years of experience in biopharmaceutical process development, manufacturing sciences, and technology with large biopharmaceutical and smaller biotechnology companies. He received his B.S. in Chemistry from [Denison University](/org/denison-university) and a Ph.D. in Biochemistry (with a minor in Analytical Chemistry) from the [University of Cincinnati](/org/university-of-cincinnati). Jim extended his education in protein chemistry and separation science with an NIH post-doctoral Fellowship at the [University of Cincinnati](/org/university-of-cincinnati) College of Medicine in the Department of Pharmacology & Cell Biophysics (mostly working with animal-derived membrane proteins from tissues) and further expanded his knowledge/ experience at the Blood Research Institute, The Blood Center of Southeastern Wisconsin, in the Department of Immunochemistry (working on human systems, Red Blood Cells and membrane proteins). He utilized all the tools gained from the advanced training to enter into biopharmaceutical process development and manufacturing, where he started at [Alexion Pharmaceuticals](/org/alexion-pharmaceuticals) and continued advancing bioprocess and people leadership at Medarex, Inc.; Abbott Bioresearch Center; [Amgen](/org/amgen); Shire HGT; Immunogen; Natrix Separations, Inc./EMD Millipore_Sigma; HOST Therabiomics, Inc.; and BioVectra, Inc./Mallinckrodt Pharmaceuticals. Jim managed many different recombinant protein programs at various stages from Research, all Clinical Phases, and Commercial and was privileged to contribute to the advancement of commercial Humira® and Enbrel®.

James Stout

Stephen serves as Shattuck’s Deputy General Counsel and Vice President of Intellectual Property. He joined Shattuck in 2021 after spending nearly 15 years in private practice with Vinson & Elkins L.L.P. and Baker Botts L.L.P. Stephen’s practice focused on federal litigation, particularly in intellectual property and technology disputes involving the life sciences and digital media. At Shattuck, he is responsible for, among other things, the company’s intellectual property portfolio. Stephen has a J.D., with honors, from the University of Texas School of Law, a Ph.D. from the University of Texas at Austin, an M.S. from Louisiana State University, and a B.S. from [Texas A&M University](/org/texas-a-m-university). He is admitted to practice law in Texas and before the U.S. Patent & Trademark Office. He is also a longtime author of the annually updated O’Connor’s Federal Intellectual Property Codes Plus, serves on the Board of Directors of Volunteer Legal Services of Central Texas, and regularly volunteers with the trial advocacy program at the University of Texas School of Law.

Stephen Stout

Tyler is Managing Director and Portfolio Manager of Lennox Capital Partners, LP, a special situations and value-oriented investment company active in public and private equity. While at Lennox, Tyler spent over a year working at [Arog Pharmaceuticals](/org/arog-pharmaceuticals) as the acting CFO, leading their capital markets and business development efforts. Prior to joining Lennox, Tyler worked as a senior analyst at YX Funds, a short-only hedge fund in Dallas. In addition, Tyler started his career in the M&A group at [Citigroup](/org/citigroup) in New York. Tyler holds a B.S. in Finance and Business Honors from the University of Texas, where he graduated Summa Cum Laude.

Tyler Brous

Erin joined [Shattuck Labs](/org/shattuck-labs) in 2017 as General Counsel. She has over 10 years of experience counseling clients in the life science industry. From 2007 to 2017, she was an Associate, and later Counsel, at the law firm of Vinson & Elkins LLP in Austin where she advised both early-stage biotech and big pharma clients on a wide range of intellectual property and other legal issues, including strategic investments, in-bound and out-bound licenses, collaborations, mergers and acquisitions, freedom to operate analyses, due diligence, assessment of IP portfolios, Hatch-Waxman litigation, biosimilars legislation, and IP and licensing disputes. Erin holds a J.D. from [Baylor University](/org/baylor-university), where she graduated Summa Cum Laude, and a B.S. in Biology from [Pepperdine University](/org/pepperdine-university). She conducted post-graduate research at the University of California, San Francisco and clerked for Chief Justice Wallace Jefferson of the Supreme Court of Texas. She is admitted to practice law in Texas and is a registered U.S. patent attorney.

Erin Ator Thomson

George Golumbeski recently joined [GRAIL](/org/grail) as President. He has more than 25 years of experience in the biotechnology industry. He currently serves on the Board of Directors of several biotechnology companies, including [KSQ Therapeutics](/org/ksq-therapeutics), [Carrick Therapeutics](/org/carrick-therapeutics), [Enanta Pharmaceuticals](/org/enanta-pharmaceuticals), and [MorphoSys](/org/morphosys). George was most recently Executive Vice President of Business Development for Celgene, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medications to people suffering from cancer and chronic inflammation. He holds a PhD in genetics from the University of Wisconsin-Madison, and conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder. George holds a bachelor’s degree in biology from the [University of Virginia](/org/university-of-virginia)

George Golumbeski

Sanjay joined Shattuck in May 2021 as Vice President of Strategic Marketing. He brings over 30 years of experience across all phases of drug development, including drug discovery, commercialization, and life cycle management, in both the biotechnology and pharmaceutical industries. Prior to joining Shattuck, Sanjay was the Senior Global Marketing Director in Global Oncology Therapeutic Area at GlaxoSmithKline (GSK). While at GSK, Sanjay was instrumental in providing commercial leadership for several early and late-stage assets in immuno-oncology, cell and gene therapy, epigenetics, and tumor signaling. Sanjay received his Ph.D. from Portland State University and holds an M.B.A. from Villanova University.

Sanjay Khandekar

Carrie is the Chief Medical Officer of Cellectis, where she is responsible for overseeing clinical research and development. Previously she held several senior leadership positions, including Vice President of Global Clinical Research and Development, Therapeutic Area Head for Myeloid Diseases at Celgene, Executive Director of Clinical Sciences Oncology at Regeneron Pharmaceuticals, and Senior Medical Director of Hematology and Oncology at Hoffman-La Roche (Roche Pharmaceuticals). Prior to her industry career, Dr. Brownstein practiced pediatric hematology and oncology at New York Presbyterian Columbia University and Mount Sinai Medical Center and completed her internship and residency at Columbia Presbyterian Medical Center in New York and her subspecialty training at Memorial Sloan-Kettering Cancer Center. Dr. Brownstein received her M.D. from Tufts University School of Medicine and received her A.B. in Psychology from the University of Michigan.

Carrie Brownstein

Ignacio Melero

Drew Pardoll is a Professor at the [Johns Hopkins University](/org/johns-hopkins-university) School of Medicine.


Drew Pardoll

Helen has 30 years of experience across the biotech, pharmaceuticals, consulting and banking industries. Helen was most recently COO of the [Bill & Melinda Gates Medical Research Institute](/org/bill-melinda-gates-medical-research-institute), a non-profit biotech focused on diseases that cause mortality, poverty and inequality in low- and middle-income countries. Previously, she served as CFO for public and private biotechs, and served in senior finance roles at [Novartis](/org/novartis) and [Pfizer](/org/pfizer), including CFO for [Novartis](/org/novartis) Global Oncology. Helen is currently a member of the board of Premier, Inc. (NASDAQ: PINC), a healthcare improvement company, and is also on the boards of two private biotech companies. Helen earned a BA in Economics, summa cum laude, from the [University of Maryland](/org/university-of-maryland), and an MBA from the Darden Graduate School of Business at the [University of Virginia](/org/university-of-virginia).

Helen M. Boudreau

Lini joined [Shattuck Labs](/org/shattuck-labs) in July 2017 as Chief Medical Officer. She brings more than 25 years of academic, medical, and pharmaceutical experience. Her broad oncology drug development expertise spans early-to-late phase development from Pre-IND through registration and commercialization. Prior to joining Shattuck, Lini was Head of Global Clinical Development and Senior Vice President at Adaptimmune, responsible for clinical development of the company’s immuno-oncology pipeline. She spent several years with GlaxoSmithKline (GSK) culminating her tenure as, Vice President R&D and Head Unit Physician for Oncology. While at GSK, Lini was instrumental in leading the development of several compounds. Lini practiced medicine in both the United Kingdom and the United States and is Board Certified in Hematology and Oncology. Lini was an attending physician at Dana Farber Cancer Institute in Boston and at Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital in Miami and held academic appointments at [Harvard University](/org/harvard) and the [University of Miami](/org/university-of-miami). She received her medical degree from The University of Liverpool, England.

Lini Pandite

Kurt Schalper

Mr. Lee is a co-founder and portfolio manager at Redmile Group, LLC, a health care-focused investment firm based in San Francisco and New York. Prior to Redmile, he worked as a biotechnology investor at Steeple Capital, and before that at Welch Capital Partners and PThanks Kimrudential Equity Group. Mike holds a B.S. in Molecular and Cellular Biology from the University of Arizona.

Michael Lee

Johann De Bono

Aurélien Marabelle

Neil has over 25 years of drug development experience and currently serves as chief scientific officer, biologics at COI Pharmaceuticals, where he is responsible for the creation of novel drug discovery companies based on innovative and disruptive technologies. Neil has over 25 years of drug development experience and currently serves as chief scientific officer, biologics at COI Pharmaceuticals, where he is responsible for the creation of novel drug discovery companies based on innovative and disruptive technologies. Neil has held various senior positions within the biotechnology and pharmaceutical industry including senior vice president, [BioAtla](/org/bioatla); chief scientific officer, [Regulus Therapeutics](/org/regulus-therapeutics); chief scientific officer and oncology therapeutic area head, [Pfizer](/org/pfizer) Oncology; and chief scientific officer, OSI Pharmaceuticals. While at [Pfizer](/org/pfizer), Neil was also a member of the [Pfizer](/org/pfizer) Oncology Business Unit Executive team. Neil has been involved in the successful discovery, development, and commercialization of four approved oncology drugs, including temozolomide, sorafenib, erlotinib, and crizotinib. While at Regulus he was responsible for leading all research and development efforts resulting in three distinct oligonucleotides being advanced into clinical development and the establishment of human proof of concept with the lead molecule RG-101. Neil has held numerous academic appointments, including associate professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the [National Cancer Institute](/org/national-cancer-institute), National Institutes of Health. During his career, he has served on the Experimental Therapeutics Study Section of the [National Cancer Institute](/org/national-cancer-institute) and has been actively involved with the American Association of Cancer Research. He is also a past president of the British Pharmaceutical Students Association. Neil earned his Ph.D. in 1982 from the University of Aston in Birmingham, England.

Shattuck Labs

Org chart

Teams

Leadership Team

Board of Directors

CEO and Executive Team

Founding Team

Discover similar companies